China’s Latest Status of New Cosmetic Ingredient Application and Market Entry

Since the implementation of the Cosmetic Supervision and Administration Regulation (CSAR) in 2021, the China National Medical Product Administration (NMPA) has adopted a classified management approach for new cosmetic ingredients (NCIs) based on their risk levels. High-risk NCIs require registration, while low/medium-risk NCIs can be "notified" through online dossier submissions, simplifying market entry.

Over the past years, interest in NCI notification has surged, with 181 notifications published in the NMPA system from June 2021 to August 2024. What are the characteristics of the notified NCIs? What challenges do enterprises face during the application process? What regulatory updates have emerged? ChemLinked invited regulatory expert Mona Zhang from REACH24H to discuss the latest developments in NCI applications.

Notes:

• The webinar livestreaming is freely available to all users. You are welcome to register for and participate in the webinar.

• Kindly be aware that the access to the slides, recording, and Q&A collection is limited to ChemLinked premium members only [Upgrade now].

• For any questions or business inquiries related to NCI registration or notification, please feel free to email us at [email protected].

Further Reading

• The Easiest Path to New Cosmetic Ingredient (NCI) Applications in China: A Case Study of Polymer Ingredients

• China Consults on Two Guidelines for Determining New Cosmetic Ingredients (NCIs)

• Pedia | China New Cosmetic Ingredient (NCI) Regulation

1. Overview of NCI Management in China

2. Analysis of Notified NCIs

3. Challenges in NCI Registration and Notification

4. Recent Updates on NCI Regulations

5. Compliance Advices

If you have any questions about this webinar, please contact us at:

EMAIL: [email protected]

TEL: +86 (0) 571 8609 4444